Fusion Pharmaceuticals Inc logo

FUSN - Fusion Pharmaceuticals Inc News Story

$8.51 0.3  3.7%

Last Trade - 9:00pm

Sector
Healthcare
Size
Small Cap
Market Cap £250.8m
Enterprise Value £87.3m
Revenue £n/a
Position in Universe 4090th / 7008

BRIEF-Fusion Pharmaceuticals To Expand Pipeline With Acquisition Of Ipn-1087, A Small Molecule Targeting Ntsr1, From Ipsen

Tue 2nd March, 2021 12:46pm
March 2 (Reuters) - Fusion Pharmaceuticals Inc  FUSN.O :
    * FUSION PHARMACEUTICALS TO EXPAND PIPELINE WITH ACQUISITION
OF
IPN-1087, A SMALL MOLECULE TARGETING NTSR1, FROM IPSEN
    * FUSION PHARMACEUTICALS - INTENDS TO USE IPN-1087 TO CREATE
ALPHA-EMITTING RADIOPHARMACEUTICAL, FPI-2059, TARGETING SOLID
TUMORS EXPRESSING NTSR1
    * FUSION PHARMACEUTICALS INC - FUSION WILL ISSUE TO IPSEN
400,000
SHARES OF COMMON STOCK UPON CLOSING
    * FUSION PHARMACEUTICALS INC - FUSION WILL ISSUE ADDITIONAL
200,000 SHARES UPON ACHIEVEMENT OF PATENT-RELATED MILESTONE
    * FUSION PHARMACEUTICALS INC - WILL ALSO BE OBLIGATED TO PAY
UP TO
AN ADDITIONAL EUR 67.5 MILLION UPON ACHIEVEMENT OF SOME
MILESTONES
    * FUSION PHARMACEUTICALS INC - DEAL INCLUDES PAYMENT OF UP
TO EUR
350.0 MILLION IN NET SALES MILESTONES

Source text for Eikon:  ID:nCNWDSBF8a 
Further company coverage:  FUSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.